ALMS Stock Summary and Trading Ideas (Alumis | NASDAQ:ALMS)

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Alumis trades on the NASDAQ stock market under the symbol ALMS.

As of February 6, 2026, ALMS stock price declined to $26.19 with 1,376,406 million shares trading.

ALMS has a beta of -2.47, meaning it tends to be less sensitive to market movements. ALMS has a correlation of 0.09 to the broad based SPY ETF.

ALMS has a market cap of $3.27 billion. This is considered a Mid Cap stock.

Last quarter Alumis reported $2 million in Revenue and -$1.06 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.09.

The top ETF exchange traded funds that ALMS belongs to (by Net Assets): IWM, VTI, IBB, IWN, SCHA.

ALMS has outperformed the market in the last year with a price return of +297.4% while the SPY ETF gained +15.1%. ALMS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +454.9% and +6.8%, respectively, while the SPY returned +3.3% and +0.2%, respectively.

ALMS support price is $24.83 and resistance is $27.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALMS shares will trade within this expected range on the day.